• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    N-Phenyl-N-(4-piperidinyl)amides have the following formula <IMAGE> in which the substituents are defined in Claim 1; the compounds can also be present as acid addition salts. The compounds of the formula I, in which Z is oxygen, are prepared by reacting a corresponding 4,5-dihydro-1H-tetrazol-5-one with a corresponding N-phenyl-N-(4-piperidinyl)amide. Compounds of the formula I, in which Z = O, are likewise obtained by N-acylating a corresponding 4-piperidinamine. Compounds in which Z = S are prepared from compounds of the formula I, in which Z = O, by reaction with a sulphurating agent. Pharmaceutical compositions having an analgesic effect contain, as the active compound component, at least one novel compound of the formula I or a pharmaceutically acceptable acid addition salt thereof.
    公开号:SU867304A3
    申请号:SU782613447
    申请日:1978-05-05
    公开日:1981-09-23
    发明作者:Эдуард Жансен Франс
    申请人:Жансен Фармасетика Н.В. (Фирма)；
    IPC主号:
    专利说明:

    (54) METHOD FOR OBTAINING DERIVATIVES OF N-PHENYL-M- (4-PIPBRIDINIL) AMIDA OR THEIR SALTS
    12
    : The invention relates to a process for the preparation of new chemical compounds of the series N-phenyl-N- (4-piperidinyl) - amide, having (4,5-dihydro-4-Y-5-oxo-1H-tetra-el-1-yl) alkyl group in the G-position

    -yyyyear
    i t
    s
    piperndinovogo dra. These are combined analgesic properties. . A known method of producing new H-phenyl-H- (4-piperidine) amides, which is represented by the general structural formula
    f -f "%) () - | -B",
    where And is hydrogen, lower alkyl, cyc-20 loalkyl, phenyl, phenyl (lower alkyl), thienyl, thienyl (lower alkyl); R is hydrogen, methyl, phenyl; R is hydrogen, lower alkyl; (lower alkyl) oxycarbonyl, (lower alkyl) oxymethyl, (lower alkyl) carbonyl; J - lower shkil, cyclopropyl; H - hydrogen, lower alkyl; 25 hydrogen, halogen, lower alkyl, lower alkyloxy, trifluoromethyl; p - O or 1; or their salts. The term lower alkyl in the sense in which it is used refers to the alkyl radicals of normal or branched structure, containing from 1 to 6 carbon atoms, such as methyl, ethyl, 1-methylethyl, 1,1-di-methylethyl , propyl, butyl, pentyl, hexyl, etc .; the term cycloalkyl refers to cycloalkyl radicals containing from 3 to 6. carbon atoms (examples of such cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl). The interaction of secondary amines with alkyl halides leads to the formation of the alkylation product C. The purpose of the invention is to obtain new derivatives of N phenyl-N- (4-piperidinyl) amide, which possess valuable properties. This goal is achieved by the fact that according to the method for producing a compound of the general formula 1 | Compounds of general formula RN y-X N-A / are reacted with N-phenyl-N- (4-piperidinyl) amide of the general formula G1 where R, R, R, R, R have the above meanings, x is hydrogen, when X is a group of formula 1U, - (: n- (sno.), Y-sn- (snd) n-th “. 4V AND“ Y or X is a group of formula Y, when X is hydrogen, 5 and ft have the above Y-halogen, in an inert organic solvent medium in the presence of a base, followed by isolation of the target product either in free form or as an acid-addition salt. Reaction 4,5-dihydro-1H-te.trazol-5-one of formula II with K-phenyl-M- (4-pipa This formula can be carried out using standard N-alkylation procedures. It is advantageous to carry out the above reaction in an environment which is suitably inert with respect to reagents / organic solvent, such as an aromatic hydrocarbon, such as benzene, methylbenzene, cymethylbenzene, and so on. d., lower alkene, for example, methanol, ethanol, 2-propanol, 1-butamol, etc., a ketone, for example, 4-methyl -2-pentanone, etc .; an ether, for example, 1,4-dioxane, distil ether, and the like; N, N -dimethylformamide, nitrobenzene, etc. To bind the acid that is released during the reaction, various acid acceptors can be used and, in particular, a suitable inorganic base, such as alkali metal carbonate or alkali metal bicarbonate, or an organic base, such as triztilamine or N- (1-methylethyl) -2-propylamine. In some cases, it is appropriate to add any iodine salt, preferably an alkali metal iodide. Elevated temperatures are used to accelerate the reaction. Under certain circumstances, especially when one of the substituents and and C. is a methyl group and the other is a hydrogen atom, a partial rearrangement may occur during the reaction, resulting in the formation of a mixture of isomers of position, in which, respectively, and methyl and K is a hydrogen atom, and vice versa ft is a hydrogen atom, and C is a methyl radical. Such position isomers can be easily separated from each other using known separation methods, such as selective crystallization from a suitable solvent system or column chromatography. Compounds of Formula D where and. - a hydrogen atom, obtained from the corresponding compound of the formula D, in which R is a phenylmethyl radical, by debenzylation of the latter by a conventional method, for example by catalytic hydrogenolysis using a suitable catalyst, such as, for example, palladium on activated carbon. In carrying out the described and subsequent syntheses, the reaction products are isolated from the reaction mixture and, if necessary, subjected to further purification by using conventional methods of isolation and purification, which are widely used in organic chemistry. A series of compounds of the formula I contain one or more asymmetric carbon atoms and, as a result, exist in different stereochemically isomeric forms. In the case where R or R has meanings other than a hydrogen atom, the carbon atoms to which they are attached are asymmetric. Additional asymmetric carbon atoms may be present in the composition of the lower alkyl groups included in and, ft and and. Although the synthesis of such compounds inevitably produces mixtures, including racemic mixtures, of such stereoisomers, these mixtures can be divided into their stereochemically pure isomeric forms using the known racemate cleavage (separation) methods, for example, by salt formation with optical isomers of disymmetric carboxylic acids and selective (fractional) crystallization of the salts thus obtained. The stereoisomeric forms of the compounds of formula I are included in the range of compounds covered by formula G.
    Due to the presence of the basic properties, the compounds of the formula I can be converted to the corresponding therapeutically active and non-toxic salts with acids by treating the compound I with an appropriate acid, among which are some inorganic acids such as hydrohalic acids (hydrochloric acid, hydrobromic acid, etc.) p.), sulfuric acid, nitric acid, phosphoric acid, etc., also organic acids such as acetic acid, glycolic acid, 2-hydroxypropanoic (lactic) acid, pyruvic acid Islota, propanedicarboxylic acid, butanedibarboxylic acid, (Z) -2-butandicarboxylic acid, (E) -2-butandicarboxylic acid, 2-hydroxybutanecarboxylic acid, 2,3-dioxybutanecarboxylic acid, 2-hydroxy-1,2, H-yropantricarboxylic acid , benzoic acid, 3, 7Phenyl-2-propenoic acid, oL-oxyphene-lousacetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, 4-methylbenzene sulfonic acid (p-toluenesulfonic acid), cyclohexane sulfamic acid “t-6-xibenzoic acid –– -oxybenzoic acid and other similar to slots. These salts may be
    The Qs are converted back to the free bases by treatment with alkali. I The compounds of the formula X and their salts with pharmaceutically acceptable acids have very interesting pharmacological properties. They are potent morphine-like analgesics and can be used as such to suppress pain in warm-blooded animals.
    0 Useful analgesic (anesthetic) properties of the compounds of formula I and their salts with acids clearly follow from the results obtained during the test
    5 to remove the tail in rats. The results in the table indicate the value of L.ED, i.e. the minimum 100% effective dose in mg / kg when administered intravenously, as well as
    . the duration (expressed in minutes) of the analgesic effect caused by administering the indicated dose. A preferred group of compounds of formula T is represented by those compounds in which R is lower alkyl. by the radical. It is these preferred compounds that are potent analgesics that have a short duration of action. Analgesics possessing such a short period of analgesic action are highly desirable means in cases where it is necessary to relieve (eliminate) acute intolerable pain for a relatively short period of time, for example in anesthesiology. In view of the fact that the compounds of the present invention show high analgesic activity, they can be formulated for the purpose of administration in various pharmaceutical forms. For the preparation of pharmaceutical compositions, effective analgesic (analgesic) amounts of a specific compound, taken as a free base or as a salt with an acid, are combined to form a thoroughly homogenized mixture with a pharmaceutically acceptable carrier, which can take a wide variety of forms depending on the type of preparation desired for administration, e.g. in the form of preparations with a dosage of the active ingredient calculated per administration, i.e. in unit dosage form suitable for oral administration, rectal route (through the rectum} or by parenteral injection. When preparing compositions as doses for oral administration, any pharmaceutical media can be used (carriers, diluents)
    such as water, glycols, oils, alcohols, etc. in the case that the challenge is to obtain liquid preparations for oral administration, such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, various lubricants and lubricants, binders, disintegrating agents, etc. - in the case when the goal is to obtain solid preparations for oral administration, namely, powders, pills, capsules and tablets. Due to the ease of administration (ingestion), tablets and capsules represent the most advantageous and convenient dosage form of the preparation for oral administration, in the manufacture of which solid pharmaceutical carriers are used. In preparing the compositions for parenteral administration, said carrier is usually sterile water, at least it accounts for the majority of the carrier (diluent) used.
    envelopes, capsules, pills, powder bags, wafers, injected solutions or suspensions, complete teaspoon potions, full teaspoon potions, etc., as well as individual packages containing many such unit dosage forms.
    In view of the fact that the proposed compounds have pronounced analgesic (analgesic) activity, it is quite obvious that they provide a way to prevent pain or combat pain in warm-blooded animals by systematically administering an effective pain reliever (relieving) of the compound of the formula D or salts with a pharmaceutically acceptable acid in mixture with a suitable pharmaceutical carrier or diluent ..
    Although the amount of the active analgesic ingredient intended
    for administration, it can be varied, although other ingredients may be included in the composition to increase the solubility of the main (active) component of the resulting composition. It is necessary to indicate the possibility of obtaining a solution for injection, in which the carrier is a saline solution, a glucose solution or a mixed glucose-saline solution. In addition, so-called injectable suspensions can be obtained, meaning that appropriate liquid carriers, suspending agents, and the like can be used. Salts of compounds of formula I with pharmaceutically acceptable acids, due to their increased solubility in aqueous media, as compared with the corresponding free bases, are more suitable substances for preparing aqueous pharmaceutical compositions. Especially advantageous is the preparation of the mentioned pharmaceutical compositions (formulations) in unit dosage form for facilitating the introduction of prepar into the body and ensuring uniformity and uniformity of dosage. The term unit dosage form refers to physically discrete pharmaceutical enzymes at a dose quality for one prima, each unit containing a predetermined amount of active ingredient being calculated so as to cause the desired therapeutic effect in combination with the desired pharmaceutical nose 1 body. Examples of such unit dosage forms are tablets (including tablets with a notch for breaking in half or into more parts, as well as on a fairly wide range depending on specific circumstances, in most cases, doses in the range of from about 0.01 mg are found effective. / kg to 1 mg / kg, administered once or repeatedly (repeatedly).
    Example 1. To the stirred mixture, parts by weight: ethyl isocyanate 14.2; sodium azide 29.2 and dry tetrahydrofuran 135 add 35 parts by weight of aluminum chloride solution. 225 parts by weight in dry tetrahydrofuran. Stirring is continued overnight at the boiling point of the reaction mixture. The reaction mixture is then cooled and acidified with 6N hydrochloric acid. The acidified mixture is evaporated to dryness and the product is extracted four times with 2-propanone. The combined extras are dried, filtered and evaporated. The residue after evaporation is dried overnight and 18 wt.h. (65%) of the target 1-Etml-1,4-dihydro-5H-tetrazol-5-one ..
    Example 2. In example 1 and using an equivalent amount of cyclohexyl isocyanate and 2-propyl eocyan a, respectively, the starting compounds are obtained: 1-cyclohexyl-1, 4-dihydro-5H-tetrazol-5-one; and 1,4-dihydro-1- (1-methylethyl) -5H-tetrazol-5 it as a residue.
    PRI am er 3. To 990 weight.h. tetrahydrofuran, cooled in an ice bath, was added in portions of 156 parts by weight. aluminum chloride and the resulting mixture is vigorously stirred until all is solid. the substance will not go into solution. This
    the solution is quickly added to the floor. sewable suspension 208 weight.h of sodium azide in 225 weight.h. dry tetrahydrofuran, after which the stirring of the reaction mixture is continued for another 1 h at boiling point. After cooling to room temperature, a solution of 54 parts by weight is added dropwise to the reaction mixture. 225 wt.h. butyric acid chloride tetrahydrofuran, maintaining the temperature below 30 ° C. Then the reaction mixture is slowly heated to boiling and stirring at this temperature is continued overnight. After cooling, the reaction of the cMeqb reaction is acidified to avl 800 weight parts. 6% hydrochloric acid solution and evaporated. The residue after evaporation is stirred in a solution of sodium bicarbonate, chloroform is added to the mixture and, after vigorously shaking, the aqueous and organic layer are separated in a separator. funnel. The aqueous phase is acidified with concentrated hydrochloric acid and the solvent is evaporated. The residue is stirred -in acetone. The residual material thus formed is filtered off
    the filtrate is evaporated. As a result, a residue of 32 parts by weight of 1,4-dihydro-1-propyl-5H tetrazol-5-one is obtained after evaporation.
    - ".
    Example p4. In Example 3 and using equivalent amounts of the corresponding acyl chlorides as the starting material, the following compounds are obtained: 1- (1,1-dimethylethyl) -1,4-dihydro-5H-tetrazol-5-one as a residue after evaporation;
    1,4-dihydro-1-pentyl-5H-tetrazol-5-one;
    1,4-dihydro-1- (2-phenylethyl) -5H-tetrazol-5-one in the form of a solid residue; 1,4-dihydro-1- (Phenylmethyl) -5H-tertZOL-5-OH; mp.152c and 1-cyclopropyl-1,4-dihydro-5H-tetraZOL-5-OH; mp.128s.
    Example 5. A mixture of 22 weight.h. 1-ethyl-1,4-dihydro-5H-tetrazol-5-one 45 parts by weight 1-bromo-2-chloroethane. A, 26 weight.h. sodium carbonate, 0.3 g / h of potassium iodide, h 240 weight.h. The 4-methyl-2-pentanone is stirred and boiled with a Dean-Stark water separator overnight. The reaction mixture is then cooled, water is added to it, vigorously shaken, and the aqueous and organic layer are separated in a separatory funnel. The aqueous phase is extracted three times with fresh portions of methylene chloride. The combined organic phases are dried, dried, filtered and evaporated. The residue after evaporation is purified by silica gel column chromatography using chloroform as eluent. Clean fractions are collected and the eluent is evaporated .. In the residue, 28.4 wt. (yield 80%) 1-2-CHLORETHYL-4-ETHIL-1,4 Dihydro-5H-tetrazol-5-one.
    Example 6: Reproduce the procedure of Example 5 and using various 1,4-dihydro-5H-tetrazol-5-ones and corresponding bromochloroalkanes as starting materials, the following 1- (chloroalkyl) -1,4-dihydro -5-tetrazol-5-ones: 1- (2-chloroethyl) -1,4-dihydro-4-propyl-5H-tetrazol-5-one as a residue after evaporation of the eluate .; 1- (2-Chloroethyl) -1,4-DIHIDRO-4- (1-Methylstil) -5H-tetrazole-.5-one as residue after evaporation of the eluate; 1- (2-chloroethyl) -4- (1,1-limethyl-ethyl) -1, 4-dihydro-5H-tetrazol-5-one as residue after evaporation of the eluate; 1- (2-chloroethyl) -1,4-dihydro-4-pentyl-5H-tetraeol-5-one as a residue; 1- (2-chloroethyl) -4-cyclohexyl-1,4-dihydro-5H-tetrazol-5-one as residue after evaporation of the eluate of the product obtained as a result of column chromatography on silica gel; 1- (2-chloroethyl) -1,4-DIHIDRO-4- (2-phenylethyl) -5H-tetrazol-5-one as residue after evaporation of 1- (3-chloropropyl) -4-ethyl-1,4 eluate -dihydro-5H-tetrazol-5-one as a residue; 1- (2-chloroethyl) -1,4-digo-4- (phenylmethyl) -5H-tetr-, sol-5-one as residue after evaporation of the eluate; 1- (2-chloroethyl) -4-cyclopropyl-1,4-dihydro-5H tetrazol-5-one as a residue after evaporation of the eluate.
    Example 7. A mixture of 49 weight.h. iodide, methyl, 10.5 weight, p. 1- (2-chloroethyl) -1,4-dihydro-5H-tetraz6l-5-pna, 15-weight, h. sodium carbonate, 0.2 weight.h. potassium iodide and 240 weight.h. The 4-methyl-2-pentanone is stirred and boiled overnight with a Dean-Stark water separator. Next, the reaction mixture is cooled, 100 weight is added to it, h. The waters and layers (aqueous and organic) are separated in a separating grill. The aqueous phase is extracted with methylene chloride. The combined organic phases are dried over a suitable desiccant, filtered and evaporated to dryness. The residue after evaporation is purified by column chromatography on silica gel using trichloromethane as eluent. Pure fractions are collected and the el is evaporated under vacuum. In the residue after evaporation, 15 weight parts are obtained. (85% yield) of the targeted 1,4-dihydro-1- (2-iodoethyl) -4-methyl-3H-tetrazol-5-one.
    Example 8. A mixture of 19.6 wt.h. 2- (2-thienyl) ethyl-4-methylbenzene sulfonate, 10 parts by weight 1- (2-chloroethyl) -1,4-dihydro-5H-tetrazol-5-one, io parts by weight sodium carbonate and 90 parts by weight The N, N-dimethylformamide is stirred and heated overnight at. The reaction mixture is cooled, 100 parts by weight are added. water and the product is extracted three times with toluene. The combined extras are dried, filtered and evaporated in vacuo to dryness. The residue after evaporation is purified by column chromatography on silica gel using a mixture of chloroform and petroleum ether (70:30 by volume) as eluent. The pure fractions collected by the collector {a, are combined and the eluent solvent is evaporated. In the remainder receive 15 weight.h. (46.5% yield) 1- (2-chlorostil) -1.4 g -dihydro-4- 2- (2-thienyl) ethyl-5H-tetrazole-5-one.
    PRI me R 9. To 4.5 weight.h. sulphinyl chloride is added dropwise with stirring a mixture of 13 parts by weight. N- l- (2-hydroxy-2-phenylethyl) -4- (methoxymethyl) -4-piperidinyl2-N-phenylpropanamide (hydrochloride) and 260 parts by weight methylene chloride. After completion of the addition, the mixture is stirred and baled. t t under reflux for several hours. Next, the reaction mixture is cooled and the solvent is evaporated. The residue after evaporation is formed with acetone. The mixture is filtered and the filtrate is treated with activated carbon. The latter is filtered off and the filtrate is evaporated. The residue obtained by evaporation is recrystallized from a mixture of acetone and 2,2-oxy-bis-propane (i.e., di-n-propyl ether). When crystallized, the product was filtered off and dried to constant weight. The result is
    10 9.2 weight.h. (61.7% of theory) of the target N-fl- (2-chloro-2-phenylethyl) -4- (methoxymethyl) -4-piperidinyl} -Y-phenylpropane monohydrochloride monohydrochloride 1, Idaid melting at 145.3 ° C.
    15
    PRI me R 10. A mixture of 45 weight.h. 2-methyloxyran, 83 parts by weight of N-f4- (methoxymethyl) -4-piperidinyl-D-N-phenylpropanamide, 25 parts by weight sodium bicarbonate, 450 weight.h. benzene and 80 weight.h.
    20 methanol was stirred and refluxed overnight. Next, the reaction mixture is evaporated and the residue is treated with water. From this mixture, the product is extracted with chloroform. The resulting chloroform extract is listened, filtered and evaporated to dryness. The residue after evaporation is converted to the corresponding hydrochloric salt in 2-propanol. The salt precipitate is filtered off and recrystallized from a mixture of 2,2-oxy-bis-propane and 2-propane, resulting in weight.h. (37% of theory) monohydrochloride {2-hydroxy-propyl) -4- (methoxy-5-tyl) -4-piperidinyl-H-phenylpropanamide.
    A solution of 37 parts by weight is added dropwise to the 14 parts by weight of sulfonyl chloride with stirring. (2-oxypropyl) -4- (metoksimetil) -4-piperidinyl 0 -N-phenylpropanamide in 360 weight.h. polyethylene chloride. After the addition of the solution is complete, stirring is continued overnight at the boiling point of the reaction mixture. Then
    5, the reaction mixture is evaporated and the residue is suspended in acetone. The product is filtered and dried to constant weight. In the end, get 31,5weight.h. (85% of theory) N - i- (2-chloropropyl) 0 -4-methoxymethyl) -4-piperidi1L | l -N-phenylpropanamy in the form of monohydrochloride.
    权利要求:
    Claims (1)
    [1]
    Example 11. A mixture of 1.8 weight.h. 1- (2-chloroethyl) -4-ethyl-1,4-dihydro5 -5H-tetrazol-5-one, 3, .45 parts by weight (methoxymethyl) -4-piperid.gil) -N-phenylpropanamide, 5 parts by weight sodium carbonate, 0.2 weight.h. potassium iodide and 240 weight.h. The 4-methyl-2-pentano0 is stirred and boiled overnight with a Dean-Stark water separator. The reaction mixture is then poured into water and the resulting layers are separated in a separatory funnel. The organic phase is dried, filtered and evaporated to dryness. The residue after evaporation is sought by a silica gel column chromatograph using a mixture of chloroform and methanol (97: 3 by volume) as eluent. Pure fractions are collected, combined and the eluent is evaporated. The residue is converted to a hydrochloric acid salt (hydrochloride) in isopropyl alcohol. The resulting salt is filtered off and recrystallized from acetone, resulting in 1.5 weight.h. (33.3% of theoretically possible yield) of the desired product — N -fl- {2- (4-ethyl-4,5-dihydro-5g -oxo-1H-tetrazol-1-yl) monohydrate monohydrate monohydrate (methoxymethyl) - 4-piperidinyl2-H-phenylphenamide panamide with a melting point of 140 ,. Example 12. Reproducing the procedure of example 11 using equivalent amounts of the corresponding starting materials gives the following compounds (after treatment of the free base with a suitable acid, these compounds are obtained in the form of the corresponding salts): Oxalate monohydrate (1: 2) (4 5-dihydro-5-oxo -4-propyl-1H-tetrazo) (methoxymethyl) 4-piperyl din-K-phenylpropanamide; m.p. 103.8) 1- {l- 2- (4,5-dihydro- (1-methylethyl) -5-oxo-1H-tetrazol-1-yl) (methoxymethyl) -4-piperidinyl-H-phenylpropanamide as a monohydrate mononitrate; m.p. 104 ,. Methyl 1- {2- (4, B-dihydro-3-oxo-4- (2- (2-thienyl) ethyl) -1H-tetra-; zol-1-yl ethyl 3-4- | (1 -oxopropyl) phenylamino-4-piperidinecarboxylic acid in the form of oxalate (1: 1) with a melting point of 162, ... N- {1-1-3- (4-ethyl-4,5-dihydro-5-oxo-1H -tetrazol-1-yl) propylZ-4- (methoxymethyl) -4-piperidinyl -H-phenylpropanamide as a hydrochloride hemihydrate with mp 182 ° C; and K-tl- {2-4,5-DIGIDRO-5 -OXO-4- (phenylmethyl) -1H-tetrazol-1-yl-ethyl} -4-. (Methoxymethyl) -4-piperidinyl 2-Y-phenylpropanamy in the form of oxalate (oxalate (1: 1) with so pl. 166.4 C. j Example 13. A mixture of 3.6 aEc.f. 1- (2-chloroethyl) -4-ethyl-1,4-dihydro-5H-tetrazol-5-one, 6 , 4 parts by weight of hydrochloride of methyl ester (l OKsopropyl) -N-phenylamino | -4-piperidinecarboxylic acid, 4 parts by weight of sodium carbonate, O, 1 part by weight of iodide of calcium and 240 parts by weight The 4-methyl-2-pentanone is stirred and boiled overnight with a water separator, Dean-Stark. The resulting reaction mixture is cooled and poured into water. The organic phase is separated, dried over a suitable desiccant, filtered and evaporated to dryness. The residue after evaporation is purified by column chromatography on silica gel using a mixture of chloroform and methanol (97: 3 by volume) as eluent. The pure fractions are collected, combined and the eluent solvent is evaporated in vacuo. The residue is converted to the oxalate salt by adding oxalic acid in acetone. The salt precipitate formed is filtered and dried to constant weight. In the end, get 1.5 weight.h. (13% of theoretically possible yield) oxalate (2: 3) 1-H 2- (4-EHYL-4,5-dihyd-g po-5-oco-1H-tetrazol-1-yl) ethyl 7-4-methyl ester C (1-oxopropyl) phenylamino1-4-pip-. Ridinocarboxylic acid with T.PL. 158 ,. EXAMPLE 14 According to the procedure of Example 13 and using equivalent amounts of the corresponding starting materials, g of perfect acid salts (oxalates) of the following compounds are obtained: methyl ester (4,5-dihydro-5-oxo-4-propyl-1H -tetrazol-1-yl) ethyl-4- (l-oxypropyl) phenylamino-J-4- piperidinecarboxylic acid as oxalate (1: 1) with m.p. 168.4c methyl ester, 5-dihydro-4- (1-methylethyl) -5-oxo-1H-tetrazol-1-. {(1-oxopropyl) phenylamino-4-piperidinecarboxylic acid in the form of oxalate (1: 1) with so pl. 184.2 ° C} 1- {2- 4- (1,1-dimethylethyl) -4,5-dihydro-5-oxo-1H-tetrazol-l-yl ethyl} -4- (1-oxopropyl) methyl ester phenylamino-4-piperidinecarboxylic acid in the form of oxalate (1: 1) with so pl. 168, lC; (4,5-Dihydro-5-pkso-4-pentyl-1H-tetrazol-1-yl) G (1-oxopr6pyl) phenylamino-4-piperidinecarboxylic acid methyl ester in the form of oxalate (1: 1) with t.cl. 153.5С; (4-cyclohexyl-4, 5-dihydro-5-ox-6-N-tetrazol-1yl) methyl ester (1-oxopropyl) phenylamino-4-piperidinecarboxylic acid in the form of oxalate (1: 1) with m.p. 173C ;: 1- {2- 4,5-dihydro-5-oxo 4- (2-phenylethyl) -1H-tetrazol-1yl ethyl} -4- {1-oxopropyl) phenylamino-4-piperidinecarboxylic acid methyl ester as oxatala (2: 3) with m.p. 162.2C: 1- {2-t4, 5-dihydro-5-OXO- .4- (phenylmethyl) -1H-tetrazol-1yl-C (1-oxopropyl) phenyl-Ho-4-piperidinecarbonic acid methyl ester in the form of oxalate (1 : 1) c. 191.7 C; 1- {2-G (4-cyclopropyl) -4, 5-dihydro-5-oxo-1H-tetrazol-1-yl-ethyl-4- (1-oxopropyl) phenylamino-4-piperidinecarboxylic acid methyl ester as a hemihydrate oxalate salt of composition 2: 3, having so pl. 155,9С; i-H 2- (4-ethyl-4,5-dihydro-5-oxo-1H-tetrazole- - "l) ethyl D-4- (phenylamino) -4-piperidinecarboxylic acid methyl ester of 2: 3 oxalate; having a melting point. Example 15. A mixture of 2.55 weight. 1,4-DIHIDRO-1-12-iodoethyl) -4-methyl-5H-tetrazol-5-one, 3.45 parts by weight N (methoxymethyl) -4-piperidinyl} -phenylpropanamide, 2 weight.h. carbon sodium and sodium, 0.2 weight.h. potassium iodide and 160 weight.h. The 4-methyl-2-pantanone is stirred and boiled overnight with a Dean-Stark water separator. The reaction mixture is then cooled, 100 weight of water is added to it and the resulting layers (aqueous and organic) are separated using a separatory funnel. The resulting aqueous phase is further extracted with methylene chloride. The combined organic phases are dried with an appropriate desiccant, filtered and evaporated to dryness. The residue is purified by column chromatography on silica gel using a mixture of chloroform and methanol (97: by volume) as eluent. Pure fractions are pooled and evaporated to distill off the eluent. The residue after evaporation is converted to the oxalate salt by adding oxalic acid in acetone. The precipitate formed in this way is separated from the mother liquor by filtration and then cross-crystallized with acetone; in the end, 2.1 weight parts are obtained (42% of the theoretically possible output of N.N. / XXAt., F, hL1, l ) the target N- {l-f2- (4,5-dihydro-4-methyl-5-oxo-1H-tetrazol-1-yl) ethyl-4- (methoxymethyl) -4-piperidinyl} -N-phenylpropanamide as an oxalate of composition 1; 1, having a mp 155.9 ° C. Example 16. According to the method of Example 15, (4,5-DIHIDRO-4-methyl-5-oxo-.1H-tetrazol-1-yl) 1 (1-oxopropyl) phenylamino-4-piperidinecarboxylic acid methyl ester is obtained in the form of oxalic acid salt composition 1: 1, with so pl. 185.9 ° C, by reacting 1,4-dihydro-1- (2-iodoethyl) -4-methyl-5H-tetrazol-5-one with methyl 4- (1-oxopropyl) phenylamino-4-piperidinecarboxylic acid. Example 17. A mixture of 3 wt.h. 1-ethyl-1,4-dihydro-5H-tetrazol-5-one 9.4 parts by weight N - 1- (2-chloropropyl) -4- (methoxymethyl) -4-piperidinyl-M-phenylpropanamide, 2.5 parts by weight sodium carbonate, 2.5 weight.h. N, N-diethylethanamine (i.e., triethylamine) and 90 weight parts. H, N-dimethylformamide is stirred and heated overnight at 70 ° C. Then the reaction mixture is cooled, 100 parts by weight is added to it. water and extract the product three times with fresh portions of toluene. The combined toluene extracts are dried over a suitable desiccant, filtered, and evaporated in vacuo to dryness. The residue after evaporation is purified twice by column chromatography on silica gel using a mixture of chloroform and methanol (97: 3 by volume) for the first time and a mixture of ethyl acetate and ethanol (99: 1 by volume) a second time. Pure fractions are collected, combined and evaporated to distill off the solvent. The residue is converted into the hydrochloric acid salt using a mixture of acetone and dipropyl ether as the medium. The precipitated salt is filtered and dried to constant weight. A total of 2.1 parts by weight, (18% of theory) of N - {1- 2- (4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl) -1-methylethide -4- (methoxymethyl) -4-piperidinyl} -N-phenylpropanamide in the form of monohydrochloride with so pl. 185, Example 18. A mixture of 1.2 weight.h. 1-ethyl-1,4-dihydro-5H-titrazol-5-one, 3.9 Bec.4. N - ti- (2-chloropropyl) -4- (methoxymethyl) -4-piperidinyl-N-phylpropane amide monohydrochloride . 2 vee.ch. carbonarga 1, 0.1 weight.h. potassium iodide and 120 weight.h. 4-methyl-2-pentanone is stirred and refluxed in. overnight using a Dean-Stark water separator for azeotropic water stripping. Next, the reaction mixture is cooled, poured into water, and the resulting layers (aqueous and organic) are separated in a separator /, L, O, Jtfyn jn ft. The organic phase is dried, filtered over a suitable desiccant, filtered and evaporated to dryness. The residue was purified by column chromatography on silica gel, using a mixture of chloroform and methanol (99: 1 by volume) as eluent. Pure fractions are collected and evaporated to remove the eluent solvent. The residue is converted to nitric acid solnitrate in acetone. The resulting salt is filtered off and twice cross-painted with a dipole ether mixture for the first time and then from acetone. In the end, get 1.5 weight.h. (30% of theoretically possible yield) of N- {l- 2 (4-etyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl) -1-methylethyl3-4 (methoxymethyl) -4- piperidinylZ-H-phenylpropanamide in the form of mononitrate, having so pl. 14b, bs Example 19. According to the procedure of Example 18, mononitrate (4,5-dihydro-5-oxo-4-phenyl-1H-tetazol-1-yl) -1-methylethyl-4- (methoxyethyl) -4-piperidinyl-N-phenylamide is obtained which means 151, gC, by reacting 1,4-dihydro-1-phenyl-5H-tetazol-5-one with (2-chloropropyl) -4 (methoxymethyl) 4-piperidinyl -N-feilpropanamide monohydrochloride. Example 20. A mixture of 3 wt.h. 1-ETHYL-1,4-dihydro-5H-tetraeol-5-one 8 Bec.HN - l- (2-chloro-2-phenylethyl) -4- (methoxymethyl) -4-piperidinyl-W-phenylpropanamide, 0, 2 weight parts iodist gallium, 5 weight.h. sodium carbonate and 13 weight.h. N, N-dimethylformamide is stirred and heated overnight at 7 ° C. Next, the reaction mixture is cooled to room temperature and 150 parts by weight is added to it. water, after which the product is extracted three times with fresh portions of toluene. The combined extras are dried, filtered and evaporated. The solid residue after evaporation is purified by column chromatography on silica gel using a mixture of chloroform and methanol in a ratio of 97: 3 by volume as eluent. Pure fractions are collected and evaporated to remove the eluent. The residue after evaporation is recrystallized from a mixture of petroleum ether and dipropyl ether. The crystallized product is separated by filtration, dried to constant weight and obtained in result of 5.7 parts by weight. (65% of theoretically possible yield) of the desired N - i-2- (4-ethyl-4,5-dihydro-5-oxo-1H-tetra-sol-1-yl) -2-phenethyl-4- (methoxy methyl-4 α-piperidinyl g-H-phenylpropanamine with a melting point of 125.7 ° C. Example 21. A mixture of 3 parts by weight of 1-ethyl-1,4-dihydro-5H-tetraeol-5-one 9.4 gpm - l- (2 chloropropyl) -4- (methoxymethyl) -4-piperidinyl-N-phenylpropanamide monohydrochloride, 2.5 weight parts N, N-diethylethanamic (triethylamine), 2.5 parts by weight of sodium carbonate and 90 weight The N | N-dimethylformamide is stirred and heated overnight at. Then the reaction mixture is cooled and 100 parts of water is added to it. The product is extracted three times with fresh portions of toluene. The combined extras are dried, filtered from the drying agent and evaporated to dryness. The residue after evaporation is purified by double column chromatography on silica gel. The first time product chromatography is carried out using chloroform-methanol (97: 3 by volume) as eluent. Whereas, during the rechromatography, a mixture of ethyl acetate and ethanol was used as eluent with respect to the Scientific Research Institute 99: 1 by volume. Pure fractions are collected and evaporated in vacuo to distill off the eluent. The residue after evaporation is converted to hydrochloric acid, by passing hydrogen chloride to a solution of the substance in a mixture of acetone and 2,2-oxy-bis-propane. The precipitated salt is separated by filtration, dried to constant weight, and 3.9 parts by weight are obtained. (33.4% of theoretically possible yield) M-1-G2- (4-ethyl-4,5-dihydro-5-oxo-1H-tetraeol-1-yl) propyl 4- (methoxymethyl) 4piperidinyl-4 - phenylpropanamide monohydrochloride, having so pl. 192.7 C. Example 22. A mixture of 5.7 parts by weight (4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl) ethyl-4- (phenylamino) -4-piperidinecarboxylic acid methyl ester, 1.9 parts by weight acid chloride cyclopropanecarboxylic acid, 2.7 parts by weight triethylamine and 68 weight.h. The toluene is stirred and refluxed overnight. Then the reaction mixture is cooled, 100 parts by weight are added. the waters and layers are separated using a separatory funnel. The organic phase is dried, the drying agent is filtered off and the filtrate is evaporated in vacuo. The residue after evaporation is purified by column chromatography on silica gel using a mixture of chloroform and methanol (98: 2 by volume) as eluent. Pure fractions are collected and treated with 1 weight.h. oxalic acid-, lots. The resulting oxalate salt (oxalate) is filtered off and recrystallized from a mixture of acetone and 2,2-hydroxy-bis-propane. In the end, get 1.5 weight.h. (17.5% of theoretically possible yield) of the target methyl ester of 4-G (cyclopropylcarbonyl) phenyl-amino-4 (4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl) ethyl-4-piperidinecarboxylic acid in the form of oxalate salts of composition 2: 3, having so pl. 181.5 ° C. The invention The method of obtaining derivatives of M-phenyl-N- (4-piperidinyl) amide of the general formula T
    - (sn) „- dHСБiй
    where H is hydrogen, lower alkyl, cycloalkyl, phenyl, phenyl (lower, 5
    alkyl), thienyl, thienyl (lower alkyl);
    类似技术:
    公开号 | 公开日 | 专利标题
    US5231101A|1993-07-27|Benzo[5,6]cyclohepta[1,2-B]pyridine derivatives and antiallergic agents comprising same
    KR100737721B1|2007-07-11|Biaryl substituted triazoles as sodium channel blockers, and a method for the preparation of the same
    JP4732354B2|2011-07-27|Bicyclic [3.1.0] derivatives as glycine transport inhibitors
    KR100229117B1|1999-11-01|Piperidine derivatives
    JPH11513382A|1999-11-16|5-membered heterocyclic compounds, pharmaceuticals containing these compounds, their use and methods for their preparation
    EP3634958B1|2021-07-21|Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
    NZ232542A|1992-06-25|N-phenyl-n-|amide derivatives; preparatory processes and pharmaceutical compositions
    CH678427A5|1991-09-13|
    RU2125565C1|1999-01-27|Derivatives of phenoxy- or phenoxyalkylpiperidine and antiviral composition based on thereof
    JP2003034689A|2003-02-07|4-heterocyclic fused-ring arylpiperidine derivatives
    CA3007972A1|2017-06-15|Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
    US4198417A|1980-04-15|Phenoxyphenylpiperidines
    FR2531707A1|1984-02-17|SUBSTITUTED TRIFLUOROMETHYLPHENYLTETRAHYDROPYRIDINES WITH ANOREXIGENIC ACTIVITY, A PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS
    JPH0673038A|1994-03-15|Biphenyl derivatives, medicinal compositions containing these compounds and their preparation
    CA2007127A1|1990-07-05|Piperidines, process for their preparation and drugs containing same
    FR2566404A1|1985-12-27|NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES, THEIR SALTS, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    SU867304A3|1981-09-23|Method of preparing derivatives of n-phenyl-n-|amide or their salts
    SU1230467A3|1986-05-07|Method of producing 1-cyclohexyl-4-aryl-4-piperidincarboxylic acids derivatives or their stereochemical isomeric forms |
    HUT71132A|1995-11-28|Bis-aryl-carbinol derivatives, pharmaceutical compositions containing them and process for producing
    US4446141A|1984-05-01|Hypotensive piperidine derivatives
    EP0129051B1|1990-07-04|Substituted indoles
    FR2528431A1|1983-12-16|NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
    FR2618436A1|1989-01-27|PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
    HU193909B|1987-12-28|Process for preparing novel 1-4-dihydropyridine-carboxamide derivatives and pharmaceutics comprising these compounds
    KR20010031839A|2001-04-16|Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
    同族专利:
    公开号 | 公开日
    HK72585A|1985-10-04|
    YU40703B|1986-04-30|
    DK152211B|1988-02-08|
    ATA322078A|1982-04-15|
    NL186861C|1991-03-18|
    CA1105464A|1981-07-21|
    HU179204B|1982-09-28|
    SE7805110L|1978-11-06|
    JPS6324995B2|1988-05-23|
    JPS53149980A|1978-12-27|
    FI64364B|1983-07-29|
    NO148747B|1983-08-29|
    FI781398A|1978-11-06|
    CH635585A5|1983-04-15|
    GB1598872A|1981-09-23|
    IT1105288B|1985-10-28|
    LU79575A1|1978-11-03|
    AT368994B|1982-11-25|
    IL54639A|1982-02-28|
    NL186861B|1990-10-16|
    DE2819873A1|1978-11-09|
    NO148747C|1983-12-07|
    CY1253A|1984-08-31|
    SE437516B|1985-03-04|
    DE2819873C2|1989-05-03|
    AU3552278A|1979-11-01|
    NZ187164A|1981-03-16|
    NO781559L|1978-11-07|
    FI64364C|1983-11-10|
    FR2389622B1|1982-05-21|
    DK193778A|1978-11-06|
    AU514360B2|1981-02-05|
    KE3429A|1984-08-10|
    IE780901L|1978-11-05|
    ES469473A1|1979-09-16|
    NL7804844A|1978-11-07|
    PH12831A|1979-09-05|
    IT7849203D0|1978-05-04|
    YU108578A|1983-01-21|
    DK152211C|1988-08-08|
    IE46836B1|1983-10-05|
    IL54639D0|1978-07-31|
    FR2389622A1|1978-12-01|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3998834A|1975-03-14|1976-12-21|Janssen Pharmaceutica N.V.|N--n-phenylamides and -carbamates|JPH0210357B2|1984-08-07|1990-03-07|Nippon Denso Co|
    USRE34201E|1989-04-20|1993-03-23|Anaquest, Inc.|N-aryl-N-[4-piperidinyl]amides and pharmaceutical compositions and methods employing such compounds|
    US5053411A|1989-04-20|1991-10-01|Anaquest, Inc.|N-aryl-N-[4-piperidinyl]amides and pharmaceutical compositions and methods employing such compounds|
    JPH08193074A|1994-11-18|1996-07-30|Nippon Bayeragrochem Kk|Herbicidal 1-cyclopropyltetrazolinones|
    JP2000327668A|1999-05-21|2000-11-28|Nippon Bayer Agrochem Co Ltd|Tetrazolinone derivative|
    JP2003515588A|1999-12-06|2003-05-07|マリンクロッド・インコーポレイテッド|New synthetic route to alfentanil, sufentanil and remifentanil|
    EP1795526A4|2004-09-14|2010-10-13|Nippon Chemiphar Co|N-substituted n-amide derivative|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US79381477A| true| 1977-05-05|1977-05-05|
    US88618878A| true| 1978-03-13|1978-03-13|
    [返回顶部]